PETRI DISH PERSPECTIVES

Episode 82: Dr. Natalie Ma on Building Virtual Humans to Predict Drug Safety

19 Nov 2026 · 54:48
Science

Description

Send us Fan Mail

After earning a PhD in molecular biology at Yale, Dr. Natalie Ma moved from the bench to the business side of science to tackle drug development’s biggest problem: roughly 90% of programs fail, often after years and millions of dollars. As co-founder and Chief Business Officer of Deep Origin, she helps build computational models that span the quantum mechanical to the whole human body. The goal is to predict drug safety before a molecule reaches an animal or a patient. Deep Origin also leads an eight-company ARPA-H consortium building a Virtual Human Avatar of Toxicology.

In this episode, Dr. Ma unpacks why drug development has a prediction problem rather than a speed problem, how animal models and new approach methodologies (NAMs) can work together, and where AI in drug discovery is overhyped versus underrated. She also shares what pharma says it wants from AI versus what it actually buys, and what PhD founders need to know about the business side.

Check out Deep Origin: https://deeporigin.com/

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #AIDrugDiscovery #DrugDiscovery #DrugSafety #Toxicology #NAMs #VirtualHuman #ComputationalBiology #AIinHealthcare #Biotech #HealthTech #WomenInSTEM #DeepOrigin

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.

Comments

No comments yet — be the first to write one.